SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application (“IND”) with the U.S. Food & Drug Administration (“FDA”) for approval to test Nupen™, Apricus Bio’s proprietary, topical NexACT-based formulation of filgrastim (Neupogen®).
